These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32229658)

  • 1. Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples.
    Huang Y; Mu J; Qi L; Ge W; Fang X; Song Y; Yuan Y; Zheng S
    Clin Chem Lab Med; 2020 Aug; 58(9):1451-1459. PubMed ID: 32229658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced detection of circulating tumor DNA by fragment size analysis.
    Mouliere F; Chandrananda D; Piskorz AM; Moore EK; Morris J; Ahlborn LB; Mair R; Goranova T; Marass F; Heider K; Wan JCM; Supernat A; Hudecova I; Gounaris I; Ros S; Jimenez-Linan M; Garcia-Corbacho J; Patel K; Østrup O; Murphy S; Eldridge MD; Gale D; Stewart GD; Burge J; Cooper WN; van der Heijden MS; Massie CE; Watts C; Corrie P; Pacey S; Brindle KM; Baird RD; Mau-Sørensen M; Parkinson CA; Smith CG; Brenton JD; Rosenfeld N
    Sci Transl Med; 2018 Nov; 10(466):. PubMed ID: 30404863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients.
    Jarmuzek P; Wawrzyniak-Gramacka E; Morawin B; Tylutka A; Zembron-Lacny A
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
    Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
    Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative characterization of tumor cell-free DNA shortening.
    Guo J; Ma K; Bao H; Ma X; Xu Y; Wu X; Shao YW; Jiang M; Huang J
    BMC Genomics; 2020 Jul; 21(1):473. PubMed ID: 32650715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin of circulating free DNA in patients with lung cancer.
    Abe T; Nakashima C; Sato A; Harada Y; Sueoka E; Kimura S; Kawaguchi A; Sueoka-Aragane N
    PLoS One; 2020; 15(7):e0235611. PubMed ID: 32634139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of circulating plasma cell free DNA fragments in patients with oral cancer and precancer.
    Desai A; Kallianpur S; Mani A; Tijare MS; Khan S; Jain M; Mathur V; Ahuja R; Saxena V
    Gulf J Oncolog; 2018 May; 1(27):11-17. PubMed ID: 30145546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refined characterization of circulating tumor DNA through biological feature integration.
    Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
    Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of circulating free tumor DNA in testicular germ cell tumor patients.
    Boublikova L; Kramarzova KS; Zwyrtkova M; Bakardjieva-Mihaylova V; Stuchly J; Rosova B; Kolostova K; Sonsky J; Kindlova E; Zachoval R; Buchler T; Trka J
    Urol Oncol; 2022 Sep; 40(9):412.e15-412.e24. PubMed ID: 35729018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples.
    Nesic M; Bødker JS; Terp SK; Dybkær K
    Biomed Res Int; 2021; 2021():5585148. PubMed ID: 34307658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric External Control to Quantify Cell Free DNA in Plasma Samples by Real Time PCR.
    Eini M; Behzad-Behbahani A; Takhshid MA; Ramezani A; Rafiei Dehbidi GR; Okhovat MA; Farhadi A; Alavi P
    Avicenna J Med Biotechnol; 2016; 8(2):84-90. PubMed ID: 27141267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
    Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
    Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of recurrently protected genomic regions in cell-free DNA found in urine.
    Markus H; Zhao J; Contente-Cuomo T; Stephens MD; Raupach E; Odenheimer-Bergman A; Connor S; McDonald BR; Moore B; Hutchins E; McGilvrey M; de la Maza MC; Van Keuren-Jensen K; Pirrotte P; Goel A; Becerra C; Von Hoff DD; Celinski SA; Hingorani P; Murtaza M
    Sci Transl Med; 2021 Feb; 13(581):. PubMed ID: 33597261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy with cell free DNA: new horizons for prostate cancer.
    Ponti G; Maccaferri M; Percesepe A; Tomasi A; Ozben T
    Crit Rev Clin Lab Sci; 2021 Jan; 58(1):60-76. PubMed ID: 32805148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct quantification of cell-free, circulating DNA from unpurified plasma.
    Breitbach S; Tug S; Helmig S; Zahn D; Kubiak T; Michal M; Gori T; Ehlert T; Beiter T; Simon P
    PLoS One; 2014; 9(3):e87838. PubMed ID: 24595313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
    Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
    Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma.
    Yamamoto Y; Uemura M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nonomura N
    Oncotarget; 2018 Apr; 9(29):20467-20475. PubMed ID: 29755665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
    Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serum cell-free DNA between postmortem and living samples.
    Fujihara J; Takinami Y; Kawai Y; Kimura-Kataoka K; Takeshita H
    Clin Chim Acta; 2021 Aug; 519():255-259. PubMed ID: 34015305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.